Details of the Drug

General Information of Drug (ID: DMWUIJE)

Drug Name

Tolmetin

Synonyms

Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1], [2], [3]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

257.279

Topological Polar Surface Area (xlogp)

2.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 95% of drug becomes completely available to its intended biological destination(s) [5]
Elimination: 7% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 116.6 micromolar/kg/day [7]
Water Solubility: The ability of drug to dissolve in water is measured as 0.22 mg/mL [4]

Chemical Identifiers

Formula: C15H15NO3
IUPAC Name: 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
Canonical SMILES: CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
InChI: InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
InChIKey: UPSPUYADGBWSHF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5509
ChEBI ID: CHEBI:71941
CAS Number: 26171-23-3
DrugBank ID: DB00500
TTD ID: D09BHB
ACDINA ID: D00687

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tolmetin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Sulfasalazine.	Rheumatoid arthritis [FA20]	[17]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Tolmetin and Leflunomide.	Rheumatoid arthritis [FA20]	[18]
-----------

Coadministration of a Drug Treating the Disease Different from Tolmetin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[19]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Repaglinide.	Acute diabete complication [5A2Y]	[20]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Glibenclamide.	Acute diabete complication [5A2Y]	[20]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Tolazamide.	Acute diabete complication [5A2Y]	[20]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Nateglinide.	Acute diabete complication [5A2Y]	[20]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Glipizide.	Acute diabete complication [5A2Y]	[20]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Tolmetin and Inotersen.	Amyloidosis [5D00]	[21]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Tolmetin and Cilostazol.	Arterial occlusive disease [BD40]	[22]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Budesonide.	Asthma [CA23]	[23]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Kanamycin.	Bacterial infection [1A00-1C4Z]	[25]
Ciprofloxacin XR	DM2NLS9	Moderate	Additive CNS depression effects by the combination of Tolmetin and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[24]
Trovafloxacin	DM6AN32	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Tolmetin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[24]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Tolmetin and ABT-492.	Bacterial infection [1A00-1C4Z]	[24]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Gentamicin.	Bacterial infection [1A00-1C4Z]	[25]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Netilmicin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Tobramycin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[24]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Etidronic acid.	Bone paget disease [FB85]	[26]
Risedronate	DM5FLTY	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Risedronate.	Bone paget disease [FB85]	[26]
Alendronate	DMY2KX9	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Alendronate.	Bone paget disease [FB85]	[26]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Tolmetin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[27]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Iodipamide.	Cholelithiasis [DC11]	[28]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Tolmetin and Levomilnacipran.	Chronic pain [MG30]	[29]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Tolmetin and Regorafenib.	Colorectal cancer [2B91]	[21]
Oxaliplatin	DMQNWRD	Moderate	Decreased renal excretion of Tolmetin caused by Oxaliplatin mediated nephrotoxicity.	Colorectal cancer [2B91]	[30]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Tolmetin and Drospirenone.	Contraceptive management [QA21]	[31]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Tolmetin and Ardeparin.	Coronary thrombosis [BA43]	[32]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Tolmetin and Danaparoid.	Deep vein thrombosis [BD71]	[32]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Tolmetin and Rivaroxaban.	Deep vein thrombosis [BD71]	[33]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Tolmetin and Sertraline.	Depression [6A70-6A7Z]	[29]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Tolmetin and Vilazodone.	Depression [6A70-6A7Z]	[29]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Tolmetin and Paroxetine.	Depression [6A70-6A7Z]	[29]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Tolmetin and Vortioxetine.	Depression [6A70-6A7Z]	[29]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Tolmetin and Milnacipran.	Depression [6A70-6A7Z]	[29]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Tolmetin and Escitalopram.	Depression [6A70-6A7Z]	[29]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Tolmetin and Desvenlafaxine.	Depression [6A70-6A7Z]	[29]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Tolmetin and Clomipramine.	Depression [6A70-6A7Z]	[29]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Tolmetin and PMID28870136-Compound-49.	Discovery agent [N.A.]	[34]
Fenfluramine	DM0762O	Moderate	Increased risk of bleeding by the combination of Tolmetin and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[29]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Cannabidiol.	Epileptic encephalopathy [8A62]	[21]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Tolmetin when combined with Ethacrynic acid.	Essential hypertension [BA00]	[35]
Benzthiazide	DMQWZ0H	Moderate	Antagonize the effect of Tolmetin when combined with Benzthiazide.	Essential hypertension [BA00]	[35]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Tolmetin and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[21]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Tolmetin and Sulfinpyrazone.	Gout [FA25]	[22]
Eplerenone	DMF0NQR	Moderate	Antagonize the effect of Tolmetin when combined with Eplerenone.	Heart failure [BD10-BD1Z]	[36]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Tolmetin when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[35]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Tolmetin when combined with Furosemide.	Heart failure [BD10-BD1Z]	[35]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Tolmetin when combined with Amiloride.	Heart failure [BD10-BD1Z]	[35]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Tolmetin when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[35]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Tolmetin when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[35]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[37]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Tolmetin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[39]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Tolmetin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[18]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Tolmetin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[40]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Tolmetin when combined with Indapamide.	Hypertension [BA00-BA04]	[35]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Tolmetin when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[35]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Tolmetin when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[41]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Tolmetin and Dipyridamole.	Hypertension [BA00-BA04]	[22]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Tolmetin and Potassium chloride.	Hypo-kalaemia [5C77]	[42]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[23]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Balsalazide.	Indeterminate colitis [DD72]	[17]
Methotrexate	DM2TEOL	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Methotrexate.	Leukaemia [2A60-2B33]	[43]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Tolmetin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[44]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Idelalisib.	Mature B-cell leukaemia [2A82]	[45]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Tolmetin and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[46]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Clofarabine.	Mature B-cell lymphoma [2A85]	[21]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Tolmetin and Ibrutinib.	Mature B-cell lymphoma [2A85]	[47]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Tolmetin and Ponatinib.	Mature B-cell lymphoma [2A85]	[48]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Exjade.	Mineral absorption/transport disorder [5C64]	[49]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Tolmetin and Panobinostat.	Multiple myeloma [2A83]	[19]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Deflazacort.	Muscular dystrophy [8C70]	[23]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Tolmetin and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[22]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Tolmetin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[50]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Tolmetin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[51]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Tolmetin and Prasugrel.	Myocardial infarction [BA41-BA43]	[21]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Tolmetin and Vorapaxar.	Myocardial infarction [BA41-BA43]	[52]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Tolmetin and Tirofiban.	Myocardial infarction [BA41-BA43]	[53]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Tolmetin and Sibutramine.	Obesity [5B80-5B81]	[29]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Tolmetin and Dexfenfluramine.	Obesity [5B80-5B81]	[29]
Metolazone	DMB39LO	Moderate	Antagonize the effect of Tolmetin when combined with Metolazone.	Oedema [MG29]	[35]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Tolmetin when combined with Polythiazide.	Oedema [MG29]	[35]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Diclofenac.	Osteoarthritis [FA00-FA05]	[54]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Tolmetin and MK-4827.	Ovarian cancer [2C73]	[21]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Aspirin.	Pain [MG30-MG3Z]	[55]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Prednisone.	Postoperative inflammation [1A00-CA43]	[23]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[23]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Tolmetin and Epoprostenol.	Pulmonary hypertension [BB01]	[56]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Tolmetin and Iloprost.	Pulmonary hypertension [BB01]	[56]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Everolimus.	Renal cell carcinoma [2C90]	[57]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Temsirolimus.	Renal cell carcinoma [2C90]	[57]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[24]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[23]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[21]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[23]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Pitolisant.	Somnolence [MG42]	[21]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Tolmetin and Naltrexone.	Substance abuse [6C40]	[58]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Tolmetin and Caplacizumab.	Thrombocytopenia [3B64]	[22]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Tolmetin and Apixaban.	Thrombosis [DB61-GB90]	[21]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Tolmetin and Cangrelor.	Thrombosis [DB61-GB90]	[22]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Tolmetin and Brilinta.	Thrombosis [DB61-GB90]	[21]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Tolmetin and Cabozantinib.	Thyroid cancer [2D10]	[59]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Sirolimus.	Transplant rejection [NE84]	[57]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Tolmetin and Tacrolimus.	Transplant rejection [NE84]	[57]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[20]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Tolmetin and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[20]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Olsalazine.	Ulcerative colitis [DD71]	[17]
Cinoxacin	DM4EWNS	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Cinoxacin.	Urinary tract infection [GC08]	[24]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Tolmetin and Plazomicin.	Urinary tract infection [GC08]	[25]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS stimulant effects by the combination of Tolmetin and Nalidixic acid.	Urinary tract infection [GC08]	[24]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[23]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Tolmetin and Betrixaban.	Venous thromboembolism [BD72]	[60]
-----------


⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Erythrosine sodium anhydrous	E00324	27872	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tolmetin 400 mg capsule	400 mg	Oral Capsule	Oral
Tolmetin 600 mg tablet	600 mg	Oral Tablet	Oral
Tolmetin Sodium eq 600mg base tablet	eq 600mg base	Tablet	Oral
Tolmetin Sodium eq 400mg base capsule	eq 400mg base	Capsule	Oral
Tolmetin 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7311).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073290.
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
9	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
10	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12	Pfizer. Product Development Pipeline. March 31 2009.
13	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
14	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
15	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
16	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
17	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
18	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
19	Cerner Multum, Inc. "Australian Product Information.".
20	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
23	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
24	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
25	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
26	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
27	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
28	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
29	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
30	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
31	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
32	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
33	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
34	Canadian Pharmacists Association.
35	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
36	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
37	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
38	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
39	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
40	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
41	McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
42	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
43	Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
44	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
45	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
46	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
47	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
48	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
49	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
50	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
51	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
52	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
53	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
54	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
55	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
56	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
57	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
58	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
59	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
60	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.